|Bid||2.58 x 2900|
|Ask||3.00 x 800|
|Day's Range||2.6500 - 2.6500|
|52 Week Range||1.0500 - 3.9400|
|Beta (3Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.33|
EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its fiscal period ended December 31, 2018 on Thursday, March 14. A live webcast will be available on the Investor Relations section of the corporate website at http://www.eyepointpharma.com. A replay of the webcast will also be available on the corporate website at the conclusion of the call.
EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a $60 million debt facility with CR Group L.P. (CRG) to retire existing debt and provide additional working capital to support the recent launch of YUTIQTM and the anticipated launch of DEXYCUTM expected later in the first quarter of 2019. The remaining net proceeds will provide additional working capital to support EyePoint’s two product launches and general operations. EyePoint also has the option, at its sole discretion, to borrow an additional $15 million prior to June 30, 2019.
EyePoint Pharmaceuticals, Inc. (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced it has commercially launched YUTIQTM in the United States. YUTIQ is the Company’s U.S. Food and Drug Administration (FDA) approved, three-year micro-insert for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company has also launched EyePoint Assist, a program to ensure access to YUTIQ for eligible patients in need of financial assistance.
EyePoint Pharmaceuticals (EYPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WATERTOWN, Mass., Jan. 28, 2019 -- EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.
CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / With the new year only a few days old, the pharmaceutical industry is already buzzing with the excitement surrounding companies who are taking innovative approaches to create a variety of effective treatment options for patients in the space. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Eyepoint Pharmaceuticals, Inc (NASDAQ: EYPT), Cocrystal Pharma Inc (NASDAQ: COCP), and Fred's, Inc (NASDAQ: FRED) are 4 pharma stocks to keep tabs on as the industry moves toward the future. Premier Health Group (OTC:PHGRF) (CSE:PHGI), a company that you may not have heard of, but could potentially benefit from looking into, recognizes the importance of investing in the future of the pharmaceutical industry, and amid this understanding, has made several key announcements in the past few months to show investors, as well as members of its 100,000 patient ecosystem, that the Company is committed to the advancement of this goal.
WATERTOWN, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today provided a 2019 commercial update. “EyePoint has made significant progress in building its commercial infrastructure in preparation for two ophthalmic product launches in the near-term,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “As a result of the diligence with which our team has worked to execute on commercial manufacturing scale-up, communicate with payors, build our distribution network and our hub for patient and physician support, I am pleased to be able to announce that along with the launch of YUTIQTM in the first quarter of calendar 2019, we also now anticipate launching DEXYCUTM in the first quarter of calendar 2019, earlier than initially expected.
WATERTOWN, Mass., Dec. 17, 2018 -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative.
Investors need to pay close attention to EyePoint Pharmaceuticals (EYPT) stock based on the movements in the options market lately.
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -46.15% and -30.57%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 5) Allakos Inc (NASDAQ: ALLK ) Allogene Therapeutics Inc ...
On a per-share basis, the Watertown, Massachusetts-based company said it had a loss of 44 cents. Losses, adjusted for non-recurring costs, were 19 cents per share. The drug delivery technology company ...
EyePoint (EYPT) gains an FDA approval for its eye therapy Yutiq to help cure chronic non-infectious uveitis affecting the posterior segment of the eye.
EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Netflix, PayPal, IBM, Others Reporting This Week Many key companies are set to report earnings this week. Bank of America has reported its quarterly results today while Morgan Stanley, Goldman Sachs, Netflix, United Airlines, Johnson & Johnson, BlackRock, and IBM will report earnings on Tuesday. On Wednesday, earnings will be released by United Rentals and […] The post Stock Market News Daily Roundup October 15 appeared first on Market Exclusive.